Publications in collaboration with researchers from Gustave Roussy Cancer Campus (48)

2023

  1. Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study

    Investigational New Drugs, Vol. 41, Núm. 5, pp. 677-687

  2. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

    European Urology

  3. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

    European Journal of Cancer

  4. Meta-analysis of perioperative immunotherapy in renal cell carcinoma: Available, but the jury is still out

    Urologic Oncology: Seminars and Original Investigations, Vol. 41, Núm. 9, pp. 391.e13-391.e21

  5. New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors

    Journal for immunotherapy of cancer, Vol. 11, Núm. 1

  6. Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study

    European Urology, Vol. 84, Núm. 3, pp. 321-330

  7. Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial

    The Lancet Oncology, Vol. 24, Núm. 11, pp. 1252-1265

2022

  1. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma

    Cancer, Vol. 128, Núm. 11, pp. 2085-2097

  2. First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial

    European Urology, Vol. 81, Núm. 3, pp. 266-271

  3. Immune Checkpoint Inhibitor Combination Therapy versus Sunitinib as First-Line Treatment for Favorable-IMDC-Risk Advanced Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials

    Biomedicines, Vol. 10, Núm. 3

  4. Immunotherapy maintenance therapy for advanced urothelial carcinoma (aUC): a comprehensive review

    Journal of Cancer Research and Clinical Oncology, Vol. 148, Núm. 5, pp. 1097-1105

  5. Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study

    ESMO Open, Vol. 7, Núm. 5

  6. Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial

    European Journal of Cancer, Vol. 160, pp. 61-71

  7. Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial

    Journal for immunotherapy of cancer, Vol. 10, Núm. 8

  8. Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial

    The Lancet Oncology, Vol. 23, Núm. 3, pp. 393-405

2021

  1. Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study

    ESMO Open, Vol. 6, Núm. 5

  2. Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: Post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease

    Japanese Journal of Clinical Oncology, Vol. 51, Núm. 8, pp. 1287-1297

  3. Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study

    Journal of Clinical Oncology, Vol. 39, Núm. 33, pp. 3725-3736

  4. Complete response and renal cell carcinoma in the immunotherapy era: The paradox of good news

    Cancer Treatment Reviews, Vol. 99

  5. Outcomes of systemic targeted therapy in recurrent renal cell carcinoma treated with adjuvant sunitinib

    BJU International, Vol. 128, Núm. 2, pp. 254-261